Canine Osteosarcoma Limb-Sparing Clinical Trial (ECIP-OSA-01)

Now enrolling. Contact the participating hospital listed below to see if your patient or dog is eligible.

Trial Overview

ELIAS Animal Health is currently conducting a study to assess safety and efficacy of ECI® in combination with a novel adjuvant as a limb-sparing treatment for large-breed dogs newly diagnosed with appendicular osteosarcoma. The study, which will be funded by a grant from Morris Animal Foundation, will be conducted in collaboration with Dr. Jeffrey Bryan and Dr. Megan Mickelson at the University of Missouri.

Trial Summary

  • Treatment includes limb-sparing surgery to remove primary tumor and ECI® immunotherapy combined with the novel adjuvant.
  • Patients must complete the 7-11 week protocol, conducted at the University of Missouri Veterinary School of Medicine, and return for periodic follow-up visits.
  • Each patient will be monitored for 12 months post-diagnosis.

Key Inclusion Criteria

  • Dog breeds eligible for this study include: Saint Bernard, Mastiffs (all types), Greater Swiss Mountain Dog, Great Dane, Leonberger, Newfoundland, Anatolian Shepherd, Rottweiler, Irish Wolfhound, Scottish Deerhound, Great Pyrenees, Bernese Mountain Dog, Dogue de Bordeaux, Cane Corso, Boerboel and Golden Retrievers.
  • Eligible patients must be newly diagnosed with appendicular osteosarcoma and must not have received prior treatment for the cancer.
  • Tumor must be in the distal radius or mid-ulnar location; no more than 1/3 radius may be affected.
  • Eligible patients must not have metastatic disease at the time of diagnosis.
  • Pet owner must be able and willing to attend all treatment and follow-up visits at the Veterinary Health Center at the University of Missouri in Columbia, MO.

*Additional inclusion/exclusion criteria may apply.

Participating Hospital

Veterinary Health Center at the University of Missouri-Columbia
Phone: 573-882-7821

To learn more about this therapy and to see if your dog or canine patient may be a good candidate for treatment, please contact the participating hospital above or contact us for more information.